Somatotype, the risk of hydroxychloroquine retinopathy, and safe daily dosing guidelines

Clinical Ophthalmology

Volumn 12, Issue , 2018, Pages 811-818

  Browning, David J ^a   Lee, Chong ^a  

^a Charlotte Eye Ear Nose/Throat Ass   (United States)

Author keywords

American Academy of Ophthalmology guidelines; Dosing guidelines; Hydroxychloroquine; Hydroxychloroquine retinopathy; Somatotype

Indexed keywords

HYDROXYCHLOROQUINE;

ADVERSE OUTCOME; AGE; AREA UNDER THE CURVE; ARTICLE; AUTOFLUORESCENCE IMAGING; BODY HEIGHT; BODY MASS; BODY WEIGHT; DIAGNOSTIC ACCURACY; DRUG SAFETY; ELECTRORETINOGRAPHY; FEMALE; GENDER; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RETINOPATHY; RETROSPECTIVE STUDY; SOMATOTYPE; VISUAL FIELD;

EID: 85047905363     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S163451     Document Type: Article

References (15)

1. Browning DJ. The prevalence of hydroxychloroquine retinopathy and toxic dosing, and the role of the ophthalmologist in reducing both. Am J Ophthalmol. 2016;166:11-11.
2. Browning DJ. Impact of the revised American academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;155(3):418.e1-428.e1.
3. Braslow RA, Shiloach M, Macsai MS. Adherence to hydroxychloroquine dosing guidelines by rheumatologists. An electronic medical record-based study in an integrated health care system. Ophthalmology. 2017;124(5):604-608.
4. Au A, Parikh V, Modi YS, Ehlers JP, Schachat AP, Singh RP. Hydroxy­chloroquine screening practice patterns within a large multispecialty ophthalmic practice. Am J Ophthalmol. 2015;160(3):561-568.
5. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415-422.
6. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453-1460.
7. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386-1394.
8. Browning DJ, Lee C, Rotberg D. The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women. Clin Ophthalmol. 2014;8:1401-1407.
9. Perlman EM, Greenberg PB, Browning DJ, Friday RP, Miller JW. Solving the hydroxychloroquine dosing dilemma with a smartphone app JAMA Ophthalmol. 2017;136(2):218-219.
10. Ogden CL, Fryar CD, Carroll MD, Flegal KM. Mean body weight, height, and body mass index, United States 1960-2002. Adv Data. 2004;347:1-17.
11. Browning DJ. Hydroxychloroquine and Chloroquine Retinopathy. 1st ed. New York: Springer; 2014:170.
12. Browning DJ. Avoiding the traps of hydroxychloroquine use. Rev Ophthalmol. 2016. Available from: https://www.reviewofophthalmology.com/article/avoiding-the-traps-of-hydroxychloroquine-use. Accessed January 23, 2018.
13. Mcchesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med. 1983;75(1A):11-18.
14. Mcchesney EW, Shekosky JM, Hernandez PH. Metabolism of chloroquine-3-14C in the rhesus monkey. Biochem Pharmacol. 1967;16(2):2444-2447.
15. Mcchesney EW, Conway WD, Banks WF Jr., Rogers JE, Shekosky JM. Studies of the metabolism of some compounds of the 4-amino-7-chloroquinoline series. J Pharmacol Exp Ther. 1966;151(3):482-493